Description

Zitaneo-PM is a triple-action oral antidiabetic medication designed to provide comprehensive glycemic control in patients with type 2 diabetes mellitus. It combines three powerful agents:

• Sitagliptin (100 mg): A DPP-4 inhibitor that enhances incretin hormone activity, promoting insulin secretion and reducing glucagon levels, leading to better postprandial glucose control.
• Metformin (500 mg): A biguanide that improves insulin sensitivity, reduces hepatic glucose production, and enhances peripheral glucose uptake to lower blood sugar levels.
• Pioglitazone (15 mg): A thiazolidinedione (TZD) that improves insulin sensitivity in muscle and fat tissues, reducing insulin resistance and improving overall glucose utilization.

This synergistic combination helps in better management of fasting and postprandial blood sugar levels, reduces insulin resistance, and minimizes the risk of diabetes-related complications. Zitaneo-PM is an effective option for patients requiring multi-targeted therapy for better glycemic control and long-term diabetes management.